Larry Sutton, MD, PhD • Chief Scientific Officer
Larry Sutton is Gladius' Scientific Founder and serves as its Chief Scientific Officer. He has 35 years of research and clinical practice experience. He served on faculty at the University of Iowa and the University of Arkansas for Medical Sciences. While at the University of Iowa he co-invented along with Dr. Ronald Jones a rapid β-lactamase diagnostic that was out licensed and marketed as Cefinase PlusTM. During his tenure in Arkansas he also worked as the Director of Clinical Microbiology at the McClellan Memorial Veterans Hospital. He is currently on faculty at Benedictine College and Miami University. He has authored over 40 patents, scientific publications, book chapters, and proceedings. He graduated from the Medical Scientist Training Program at the University of Iowa where he earned his M.D. and Ph.D. in physical organic chemistry. He completed specialty training in Clinical Pathology at the University of Iowa and in Primary Care at Broadlawns Medical Center in Des Moines, Iowa.
Georgina Kilfoil • Head of Project Managament
Georgina Kilfoil has almost thirty years of experience with a proven track record in building, growing, and financing life-science ventures with specific expertise in strategic drug development, operational project management, and clinical plan execution. Most recently, Ms. Kilfoil was Chief Development Officer at Benitec Biopharma. Over the past twenty years, Ms Kilfoil has been involved with, and in some cases led the development behind, several marketed anti-infectives such as doripenem (Doribax®), ceftolozane/tazobactam (Zerbaxa®), ceftaroline (Teflaro®), anidulafungin (Eraxis®). Ms Kilfoil is a certified Project Management Professional, has a Bachelor of Science Honours Degree in Pharmacology from the University of Bristol, United Kingdom, and a Master of Business Administration from the Australian Graduate School of Management, Sydney, Australia.
Martin Maguire, PhD • Head of Chemistry
Dr. Maguire was trained in organic and medicinal chemistry and has experience in key management roles during his over 25 years in the pharmaceutical and biotechnology industries. Dr. Maguire began his career at Rhone-Poulenc Rorer (now Sanofi-Aventis) and has established an outstanding track record in building up medicinal chemistry groups and infrastructure which he acquired during his tenure at Millennium Pharmaceuticals, Helios Pharmaceuticals and UCB Pharma. He has worked on multiple therapeutic targets and chemical classes that include calcium channel antagonists, adenosine agonists, tyrosine kinase inhibitors, MMP inhibitors, cholesterol biosynthesis inhibitors, MC4 antagonists, MCH antagonists and sigma agonists.
Dr. Maguire is a co-founder of Milestone Pharmaceuticals in Montreal, Canada. While at Milestone, as Vice President of Medicinal Chemistry, he was responsible for the internal discovery of etripamil, a short acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia. Dr. Maguire continued on in the role of Vice President of Chemistry and Manufacturing, developing a nasal formulation for etripamil and managing drug substance and drug product development through the completion of Phase 2 clinical trials. Etripamil has continued to advance and is currently progressing through a Phase 3 clinical trial.
Dr. Maguire received his Ph.D. in Organic Chemistry from Boston College in 1988 and subsequently completed a 2-year postdoctoral fellowship at the University of California, Berkeley.
Marc Vidal, PhD • Head of Chemistry, Montreal
Dr. Vidal is a research scientist at Gladius Pharmaceuticals where he designed and executed multiple step synthesis for the elaboration of a library of cephalosporin-based compounds for the treatment of multi-drug-resistant bacterial infections. Dr. Vidal holds a chemical engineering degree from École nationale supérieure d'ingénieurs de Caen (ENSICAEN), France. He then received is PhD in Organic Chemistry from the Université de Montréal, Canada, where he developed and studied a new class of anion transporters. Following his PhD, Dr. Vidal performed postdoctoral studies at Université de Montréal, Canada, where he developed molecularly imprinted polymers for the capture of small compounds.
Paul Truex • Executive Chairman
Paul F. Truex is currently Executive Chairman of Anthera Pharmaceuticals and served as President and CEO between 2004-2016. He was responsible for negotiating Anthera's multiple product licenses from Eli Lilly and Amgen and led Anthera's successful Initial Public Offering in 2010. Prior to founding Anthera Pharmaceuticals, Mr. Truex served as a Founder, Director, President and CEO of Peninsula Pharmaceuticals where Mr. Truex raised over $81 million of institutional capital (including $21 million from a strategic partner) and negotiated both of Peninsula's product agreements with Shionogi & Co., Ltd. and Takeda Chemical Industries. Peninsula was acquired by Johnson and Johnson in April of 2005 for $245 million in an all-cash transaction. The remaining entity, Cerexa was subsequently acquired by Forrest Laboratories for $480 million in cash.
During his career, Mr. Truex has been involved in life science transactions of over US$3 billion including Initial Public Offerings, M A, in-licensing, out-licensing and venture financing. This includes over $300 million in venture capital investments and more than $800 million in various public equity and debt offerings including Anthera's Initial Public Offering in 2010 and Versicor's IPO in 2000. Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Vicuron (Acquired by Pfizer, NASDAQ: MICU) where he directed early commercial efforts for their infectious disease portfolio. Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he was involved and led various business development transactions including Lilly's joint venture with Icos for the development of Cialis®, (NASDAQ: ICOS) and out-licensing of Eraxis® to Vicuron. Mr. Truex held escalating roles in marketing and sales and was involved in the launch of three different products for the primary care physician market.
Mr. Truex obtained his Masters of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo. Mr. Truex is currently a Director of CymaBay Therapeutics (NASDAQ: CBAY), Anthera Pharmaceuticals (NASDAQ: ANTH), Feldan Therapeutics (Private), Gladius Pharmaceuticals (Private) and LQT Therapeutics (Private). His past board appointments include Peninsula Pharmaceuticals, Trius Therapeutics (NASDAQ: TSRX), Eiger Pharmaceuticals (NASDAQ: EIGR), and Protagonist Therapeutics (NASDAQ: PTGX). He joined Milestone's Board of Directors in 2012 and was Chairman of the Board from 2012 until 2016. Mr. Truex is also a member of the Indiana University West Coast Advisory Board for the Johnson Center of Entrepreneurship and Innovation.
Lynda Choquette • Director of Finance
Lynda has over 20 years of experience in accounting, finance and tax with start up technology companies. During her eight years at Ernst & Young, she worked with several technology companies which were primarily active in the healthcare sector. After EY, she worked for other Public and Private technology companies.
Lynda holds a Bachelor in Business Administration and a Graduate Certificate in Chartered Professionnal Accountant from the Haute Etudes Commercials of Montreal and she is a member of Quebec Order of Chartered Professional Accountants (CPA).